分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

Molecular architecture responsible for specific inhibition of oncogenic PI3Kα mutants by RLY-2608 and STX-478

Xiao Liu, Yanyan Chen, Guanyi Li, Anqi Chen, Qingtong Zhou, Ming-Wei Wang

Journal:Acta Pharmaceutica Sinica B

IF:14.6

DOI:10.1016/j.apsb.2026.07.003

PMID:

Published:2026-07-05

research field:生物材料生物医学工程骨科感染控制组织工程

Abstract

Hotspot mutations in phosphoinositide 3-kinase alpha (PI3K α ), such as H1047R, E542K, and E545K, drive tumorigenesis across multiple cancer types. Orthosteric PI3K α inhibitors are effective but have toxicity against wild-type PI3K α , the emergence of resistance, and a narrow therapeutic index. Allosteric inhibitors such as RLY-2608 and STX-478 offer a promising path toward mutant-specific suppression, yet the structural basis for their selectivity and mechanisms of action remain elusive. Here, we report high-resolution cryogenic electron microscopy structures of RLY-2608- and STX-478-bound H1047R, E542K, and E545K, revealing a shared cryptic allosteric pocket, accessible only through a major conformational rearrangement of the activation loop that is stabilized in oncogenic mutants. While both inhibitors occupy this pocket, they have distinct interaction networks and propagate divergent allosteric activities: RLY-2608 induces large-scale remodeling of catalytic and membrane-interacting elements, whereas STX-478 reinforces autoinhibitory interfaces between p110 α and p85 α subunits. Comparative analysis provides structural insights into their differentiated potency and selectivity.

本文使用的Yeasen产品

购物车
客服
转染试用